Sociedad Americana de Hirudoterapia

Deep vein thrombosis in arthroscopic surgery and chemoprophylaxis recommendation in an Asian population

Research article published in Singapore medical journal (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosYeo KS et al. · Singapore medical journal, 2016

Abstract

INTRODUCTION: There are currently no guidelines supporting the use of routine chemoprophylaxis to prevent deep vein thrombosis (DVT) in arthroscopic surgery. Studies and meta-analysis show opposing views on its routine use in arthroscopy. This study aimed to examine the incidence of DVT in a prospective cohort of knee arthroscopy and knee arthroplasty patients, and to analyse the risk factors contributing to DVT. METHODS: All patients scheduled to undergo knee arthroscopy or arthroplasty over a two-year period were included. A standardised regimen of postoperative mechanical prophylaxis and rehabilitation was applied to all patients. Only patients who were postoperatively symptomatic were referred for ultrasonography. DVT incidence was calculated, and univariate and multivariate analyses of the risk factors were performed. RESULTS: The overall incidence of DVT was 0.5% among the 1,410 arthroscopy patients and 3.1% among the 802 arthroplasty patients. The incidence of proximal DVT among the arthroscopy and arthroplasty patients was 0.4% and 1.1%, respectively. Multivariate analysis showed that age was the only significant predictor of DVT incidence. Using the receiver operating characteristic method, the cut-off age for the arthroscopy and arthroplasty patients was 52 years, while that for the arthroscopy patients only was 40 years (increased risk of DVT: 5.46 and 6.44 times, respectively; negative predictive value: 99.7% and 99.8%, respectively). CONCLUSION: DVT incidence among Asian arthroplasty and arthroscopy patients remains low, even without chemoprophylaxis. Since age was found to be a significant risk factor for DVT, DVT prophylaxis can be considered for patients in high-risk age groups.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdultArthroplastyArthroplasty, Replacement, KneeAsian PeopleFemaleHumansIncidenceKnee JointMaleMiddle AgedMultivariate AnalysisProspective Studies

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta cohorte prospectiva realizó un seguimiento de la trombosis venosa profunda sintomática después de artroscopia y artroplastia de rodilla en una población asiática, reportando una baja incidencia general de DVT (0.5% artroscopia, 3.1% artroplastia) e identificando la edad como el único predictor significativo, lo que llevó a los autores a sugerir quimioprofilaxis selectiva en lugar de rutinaria. Para la hirudoterapia, la conexión es contextual más que directa: ayuda a enmarcar el panorama de riesgo de trombosis y anticoagulación de fondo en el que a veces se discuten la terapia con sanguijuelas y los anticoagulantes derivados de sanguijuelas, pero el estudio no involucra sanguijuelas ni agentes derivados de sanguijuelas. La advertencia honesta es que esta es una cohorte de una sola población sobre la epidemiología de la DVT quirúrgica y las decisiones de profilaxis; no ofrece datos sobre la hirudoterapia y no debe presentarse como un respaldo a la misma, sino solo como parte del contexto más amplio de la evidencia sobre tromboembolismo venoso.

Citación

Deep vein thrombosis in arthroscopic surgery and chemoprophylaxis recommendation in an Asian population.

Yeo KS et al. · Singapore medical journal, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.